iSBTc 20th Annual Meeting

(Some presentations are available for viewing. Please click the Slides availableicon to view the slides from that talk.)

Friday, November 11, 2005
8:15 am -
9:00 am
Keynote Address: Overcoming Immunosuppression / Tolerance in Cancer Patients
James Allison, PhD
Memorial Sloan-Kettering Cancer Center
9:00 am -
11:45 am
Click to view presentation Plenary Session: Overcoming Immunosuppression / Tolerance in Cancer Patients
Chairs: Thomas F. Gajewski, MD, PhD
University of Chicago

Elizabeth M. Jaffee, MD
Johns Hopkins University
9:00 am -
9:30 am
Click to view presentation How Host Cells Sink Anti-tumor Responses by Competing for Activating Cytokines
Nicholas P. Restifo, MD
National Cancer Institute
9:30 am -
9:45 am
Click to view presentation IL-2 Paradoxically Controls Tolerance and Immunity to a Tumor/Self-antigen
Paul A. Antony, MD
National Cancer Institute - Surgery Branch
9:45 am -
10:15 am
Immunological Targeting of Tumor Stroma: Destruction of Cancer Variants and the Immunosuppressive Microenvironment
Hans Schreiber, MD, PhD
University of Chicago
10:15 am -
10:30 am
Pharmacological Inhibition of the Immunomodulatory Enzyme Indoleamine 2,3-Dioxygenase (IDO) Cooperatively Leverages Cytotoxic Chemotherapy
Alexander J. Muller, PhD
Lankenau Institute for Medical Research
11:00 am -
11:30 am
Click to view presentation Recruitment of High Avidity Antigen Specific T Cells with T Regulatory Cell Modulation
Elizabeth M. Jaffee, MD
Johns Hopkins University
11:30 am -
11:45 am
Intra-tumoral IL-12 + GM-CSF Microsphere Therapy Induces Activation of Tumor-associated T-Effector/Memory Cells, Exodus of CD4+ CD25+ T-Suppressors and Infiltration of CD8+ T-Effectors
Nejat K. Egilmez, PhD
University of Louisville
1:00 pm -
3:00 pm
Plenary Session: New Agents in Development
Chairs: Rachel W. Humphrey, MD
Bristol-Myers Squibb

Jonathan Skipper, PhD
Ludwig Institute for Cancer Research
1:00 pm - 1:15 pm Tumor Therapy with Proteasome Inhibitor Bortezomib (Velcade, PS- 341) Plus Death Receptor (DR5) Agonist Antibody MD5.1
Anil Shanker, PhD
National Cancer Institute
1:15 pm - 1:45 pm The Role of Invariant NKT Cells in Enhancing Antigen Specific T and B Cell Responses
Vincenzo Cerundolo, MD, PhD
University of Oxford
1:45 pm - 2:00 pm Click to view presentation Identification of a Well-tolerated Outpatient Regimen of Interleukin-21 in Patients with Metastatic Melanoma and Renal Cell Carcinoma
John A. Thompson, MD
University of Washington
2:00 pm - 2:15 pm Proteasome Inhibition Upregulates the Cell Surface Expression of Receptors for IFN-ã and TNF-á on Murine Neuroblastoma Cells and Enhances the Proapoptotic and Overall Antitumor Activity of Systemic Cytokine Therapy in Murine Neuroblastoma Tumors
Tahira Khan, PhD
National Cancer Institute
2:15 pm - 2:45 pm Building Up Molecularly Defined Vaccines for Immunotherapy of Cancer
Pedro J. Romero, MD
Ludwig Institute for Cancer Research
2:45 pm - 3:00 pm Click to view presentation Induction of Therapeutic Breast Cancer Immunity with an IL-2 Immunotoxin
Keith Knutson, PhD
Mayo Clinic
3:30 pm -
5:15 pm
Concurrent Session I: Immune Monitoring
Chairs: James W. Mier, MD
Beth Israel Deaconess Medical Center

Carmen Scheibenbogen, MD
Charité, Campus Benjamin Franklin
3:30 pm - 4:00 pm Monitoring Mage Vaccination. Insights into Mechanisms of Tumor Regression
Pierre Coulie, MD
Universite Catholique de Louvain
4:00 pm - 4:15 pm Click to view presentation Metastatic Prostate Cancer Patients Treated with GVAX® Vaccine for Prostate Cancer Develop Immunoreactivity to Filamin: Role of Filamin in Prostate Cancer Metastasis
Manjula Chinnappa, PhD
Cell Genesys
4:15 pm - 4:45 pm Factors that Influence Responses to Adoptive Cancer Immunotherapy
Paul F. Robbins, PhD
National Cancer Institute - Surgery Branch
4:45 pm - 5:00 pm Click to view presentation Systematic Analysis of Anti-NY-ESO-1 T Cell Responses Reveals Striking HLA-dependent Immunodominance
Weisan Chen, PhD
Ludwig Institute for Cancer Research
5:00 pm - 5:15 pm Click to view presentation GM-CSF Can Modulate the Migratory Phenotype of Vaccine-induced T Cells by Enhancing CXCR3 Expression
Il-Kang Na, MD
Charité, Campus Benjamin Franklin
3:30 pm -
5:15 pm
Concurrent Session II: Cytokines: Biology and Therapeutics
Chairs: William E. Carson, MD
Ohio State University

Geoffrey R. Weiss, MD
University of Virginia Medical Center
3:30 pm - 3:45 pm Microarray Analysis for Monitoring the Response to Interferon
Eleonora Arico’, MD
National Institute of Health
3:45 pm - 4:00 pm Interleukin-29 Mediates Potent Anti-tumor Activity in the RenCA Model of Renal Cell Carcinoma
Pallavur V. Sivakumar, PhD
Zymogenetics, Inc.
4:00 pm - 4:15 pm Intratumoral Injection of IL-2 Plasmid Followed by Electroporation for Cancer Therapy
Holly Horton, PhD
Vical, Inc.
4:15 pm - 4:45 pm Click to view presentation A CWG 3-arm Phase II Trial of GP100 (209-2M) Peptide + High Dose Interleukin-2 in HLA-A2+ Advanced Melanoma Patients
Jeffrey A. Sosman, MD
Vanderbilt University
4:45 pm - 5:15 pm Expansion of CD4 + CD25 + Regulatory T Cells During Lymphopenia and Following IL2 Therapy
Crystal Mackall, MD
National Cancer Institute - Pediatric Oncology
3:30 pm -
5:15 pm
Concurrent Session III: Novel Approaches to Monoclonal Antibodies
Chairs: Alan L. Epstein, MD, PhD
University of Southern California, Keck School of Medicine

Louis M. Weiner, MD
Fox Chase Cancer Center
3:30 pm - 4:00 pm Click to view presentation Stepping Stones Toward Cancer Immunotherapy
Alan L. Epstein, MD, PhD
University of Southern California, Keck School of Medicine
4:00 pm - 4:15 pm Click to view presentation Phase I Trial of Siplizumab in CD2-positive Lymphoproliferative Disease
John Janik, MD
National Cancer Institute - Metabolism Branch
4:15 pm - 4:45 pm New Directions for Monoclonal Antibody Therapy
Louis M. Weiner, MD
Fox Chase Cancer Center
4:45 pm - 5:00 pm Genetic Immunization and Antibody Generation in Research Animals by Intravenous Delivery of Plasmid DNA
Mary Kay Bates, MS
Mirus Bio Corporation
5:00 pm - 5:15 pm Click to view presentation A Phase I Trial of Interleukin-12 with Trastuzumab and Paclitaxel for HER2-overexpressing Malignancies
Julie Roda
Ohio State University
Saturday, November 12, 2005
8:15 am -
9:00 am
Keynote Address:
Large-scale Genomic Methods to Dissect Cancer Phenotypes

Garrett Hampton, PhD
Genomics Institute
9:00 am -
11:45 am
Plenary Session: Genomics / Proteomics of Tumors and the Host Response
Chairs: Francesco Marincola, MD
National Institutes of Health

Emanuel Petricoin, MD
George Mason University
9:00 am - 9:30 am Gene Profiling of BCC Treated with the Immunomodifier Imiquimod (ALDARA ™) Reveals Key Signatures of Tumor Rejection
Monica Panelli, PhD
National Institutes of Health
9:30 am - 9:45 am High Mobility Group B1 Matures Dendritic Cells and is a DAMP, Elevated in the Serum of Hepatoma Patients with Chronic Hepatitis C and Diminishing Following Resection and Orthotopic Liver Transplantation or Radiofrequency Ablation
Michael T. Lotze, MD
University of Pittsburgh
9:45 am - 10:00 am Click to view presentation Inflammatory Protein Profile During Systemic High Dose Interleukin-2 Administration
Leonardo Rossi, PhD

National Institutes of Health - Immunogenetics Section
10:00 am - 10:30 am Click to view presentation A Novel Two-gene Expression Ratio that Predicts Clinical Outcome in Breast Cancer Patients Treated with Tamoxifen
Dennis C. Sgroi, MD
Harvard Medical School
11:00 am - 11:15 am Signaling Networks in Cutaneous Melanoma Metastasis Identified by cDNA Microarrays
Ulrich R. Hengge, MD
University of Dusseldorf
11:15 am - 11:45 am Proteomic Profiling of Cancer Tissues: Moving Towards Individualized Therapy
Julia Wulfkuhle, PhD
George Mason University
1:00 pm -
2:20 pm
Presidential Session
Chair: Ulrich Keilholz, MD
Charité, Campus Benjamin Franklin
1:00 pm - 1:20 pm Click to view presentation Characterization of Primary and Immune Escape Variant of HER- 2/NEU Overexpressing Mouse Mammary Carcinoma
Masoud H. Manjili, PhD
Virginia Commonwealth University
1:20 pm - 1:40 pm Click to view presentation CD4 Cells can be More Efficient at Tumor Rejection than CD8 Cells
Ainhoa Pérez-Diez, PhD
National Institutes of Health
1:40 pm - 2:00 pm WT1-Peptide Vaccination in Patients with Acute Myeloid Leukemia Shows High Immunogenicity Associated with Clinical Activity
Anne Letsch, MD
Charité, Campus Benjamin Franklin
2:00 pm - 2:20 pm Click to view presentation Mechanism of Caspase Independent Activation Induced Cell Death of Human Primary Cytotoxic T Lymphocytes: Implications for Cancer Immunotherapy
Arvind Chhabra, PhD
University of Connecticut Health Center
2:45 pm -
4:30 pm
Concurrent Session I: Cellular Therapies for Solid and Liquid Tumors
Chairs: Jerome Ritz, MD
Dana-Farber Cancer Institute

James C. Yang, MD
National Cancer Institute
2:45 pm - 3:15 pm Improving Immunotherapy Targeted at Subdominant Tumor Antigens
Helen E. Heslop, MD
Baylor College of Medicine
3:15 pm - 3:45 pm Click to view presentation Treatment of Patients with Metastatic Melanoma by Infusion of Anti-MART-1 TCR-Gene Engineered Lymphocytes
Richard Morgan, PhD
National Cancer Institute - Surgery Branch
3:45 pm - 4:00 pm TCR in Renal Cell Carcinoma: Models, Monitoring and Therapy
Dolores J. Schendel, MD, PhD
Institute of Molecular Immunology
4:00 pm - 4:15 pm Hematopoietic Stem Cell Transplant with Lymphodepletion Augments T Cell-based Adoptive Immunotherapy
Claudia Wrzesinski, PhD, DMV
National Cancer Institute
4:15 pm - 4:30 pm Click to view presentation Ex-vivo Heat Shock Protein 70-Peptide-activated, Autologous Natural Killer Cells Adoptive Therapy: From the Bench to the Clinic
Valeria Milani, MD, PhD
Ludwig Maximilian University
2:45 pm -
4:30 pm
Concurrent Session II: Signal Transduction Inhibitors
Chairs: George Coukos, MD, PhD
University of Pennsylvania Medical Center

Jeffery A. Sosman, MD
Vanderbilt-Ingram Cancer Center
2:45 pm - 3:00 pm Prostaglandin E2-mediated Receptor Signaling and Control of Breast Tumor Metastasis by Natural Killer Cells
Namita Kundu, PhD
University of Maryland School of Medicine
3:00 pm - 3:15 pm COX-2 Inhibition in Tumor Cells Blocks Arginase I Induction in Myeloid Supperssor Cells
Augusto Ochoa, MD
Louisiana State University
3:15 pm - 3:30 pm Click to view presentation Isoform-specific Gene Targeting for Cancer Therapy with Small Interfering RNA (siRNA)
Lin Zhang, MD
University of Pennsylvania
3:30 pm - 4:00 pm A Novel Mechanism of Herceptin Resistance and Counteracting Strategies
Dihua Yu, MD, PhD
MD Anderson Cancer Center
4:00 pm - 4:30 pm The Insulin-like Growth Factor Receptor-I as a Strategic Target for Antibody Therapeutics Against Cancer
Michael G. Atkins, MD
Beth Israil Deaconess Medical Center
4:45 pm -
5:45 pm
Poster Discussion Session
Chairs: Jared A. Gollob, MD
Duke University Medical Center

Craig L. Slingluff, Jr., MD
University of Virginia
4:45 pm - 5:00pm NK Cell/Macrophage Role in Antitumor Immunity
Jerome Ritz, MD
Dana-Farber Cancer Institute
5:00 pm - 5:15 pm Novel Antigens for Tumor Immunotherapy
Jonathan Skipper, PhD
Ludwig Institute for Cancer Research
5:15 pm - 5:30 pm New Tumor Vaccine Approaches
Thomas F. Gajewski, MD, PhD
University of Chicago
5:30 pm - 5:45 pm Cytokines and Tumor Immunology
Jon M. Wigginton, MD
National Cancer Institute
Sunday, November 13, 2005
8:00 am -
8:45 am
Richard V. Smalley, MD Memorial Lectureship
Steven A. Rosenberg, MD, PhD
National Cancer Institute
8:45 am -
11:00 am
Plenary Session: Turning Immunization into Tumor Regression: Obstacles and Strategies
Chairs: Johannes Vieweg, MD
Duke University

Jeffrey S. Weber, MD, PhD
University of Southern California, Norris Cancer Center
8:45 am - 9:15 am Click to view presentation Molecular Manipulation of the Anti-tumor Immune Response
Drew M. Pardoll, MD, PhD
Johns Hopkins University
9:15 am - 9:30 am Evaluation of Myeloid Suppressive Cells in Peripheral Blood of Melanoma Patients and Their Modualtion by a Heat-shock Protein -96 and GM-CSF-based Vaccine
Licia Rivoltini, MD
Istituto Nazionale Tumori
9:30 am - 9:45 am Click to view presentation Potent Immunity Achieved by Targeted, Sequential Administration of Recombinant DNA Vectors and Anchor-modified Epitope Peptides
Adrian Bot, MD, PhD
MannKind Corporation
9:45 am - 10:00 am Polarized DC1-based Therapeutic Cancer Vaccines
Pawel Kalinski, MD, PhD
University of Pittsburgh
10:00 am - 10:15 am Rescuing Anti-melanoma CD4+ Responses with Type-1 Polarized Dendritic Cells: Essential Roles of Extended IL-12 Family Members
Amy Wesa, PhD
University of Pittsburgh
10:15 am - 10:30 am Click to view presentation In Situ Targeting of Antigen Presenting Cells within Secondary Lymphoid Organs as a Means to Control Immune Responses
Kent A. Smith, MA
MannKind Corporation
10:30 am - 11:00 am Click to view presentation Making Vaccines Work: Translating Basic and Preclinical Immunology into Human Immunotherapies
Nicholas P. Restifo, MD
National Cancer Institute

Creative Commons License
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.